

Synthesis and properties of differently charged chemiluminescent acridinium ester labels

(Supplementary Material)

Anand Natrajan* and David Sharpe

Siemens Healthcare Diagnostics

Advanced Technology and Pre-Development

333 Coney Street

East Walpole, MA 02032

* Author to whom correspondence should be directed.

E-mail: anand.natrajan@siemens.com

Phone: 1-508-660-4582

Fax: 1-508-660-4591

Table of Contents

1. HPLC traces of synthetic intermediates and acridinium esters **9**, **13** and **14** (Figures S1-S9).
2. Chemiluminescence emission profiles of acridinium esters **9**, **13** and **14** in the absence of CTAC surfactant (Figure S10).
3. Chemiluminescence stability of anti-HBsAg antibody conjugates of acridinium esters **9**, **13** and **14** at 4°C (Figure S11).





Figure S1. HPLC trace of compound **2**. HPLC conditions: Phenomenex C₁₈, 10 micron, 3.9 x 300 mm column, 30 minute gradient of 10 → 100% MeCN/water (each with 0.05% TFA), 1 mL/minute, UV detection at 260 nm.







Figure S2. HPLC trace of compound **3a**. HPLC conditions: Phenomenex C₁₈, 10 micron, 3.9 x 300 mm column, 30 minute gradient of 10 → 100% MeCN/water (each with 0.05% TFA), 1 mL/minute, UV detection at 260 nm.



3a





Figure S3. HPLC trace of compound **3b**. HPLC conditions: Phenomenex C₁₈, 10 micron, 3.9 x 300 mm column, 30 minute gradient of 10 → 100% MeCN/water (each with 0.05% TFA), 1 mL/minute, UV detection at 260 nm.



3b





Figure S4. HPLC trace of compound **5**. HPLC conditions: Phenomenex C₁₈, 10 micron, 3.9 x 300 mm column, 30 minute gradient of 10 → 100% MeCN/water (each with 0.05% TFA), 1 mL/minute, UV detection at 260 nm.







Figure S5. HPLC trace of compound **6**. Phenomenex C₁₈, 10 micron, 3.9 x 300 mm column, 30 minute gradient of 10 → 70% MeCN/water (each with 0.05% TFA), 1 mL/minute, UV detection at 260 nm.







Figure S6. HPLC trace of compound **8**. HPLC conditions: Phenomenex C₁₈, 10 micron, 3.9 x 300 mm column, 30 minute gradient of 10 → 70% MeCN/water (each with 0.05% TFA), 1 mL/minute, UV detection at 260 nm.







Figure S7. HPLC trace of compound **9**. HPLC conditions: Phenomenex C₁₈, 10 micron, 3.9 x 300 mm column, 30 minute gradient of 10 → 70% MeCN/water (each with 0.05% TFA), 1 mL/minute, UV detection at 260 nm.



9





Figure S8. HPLC trace of compound **12**. HPLC conditions: Phenomenex C₈, 5 micron, 4.6 x 100 mm column, 40 minute gradient of 10 → 60% MeCN/water (each with 0.05% TFA), 1 mL/minute, UV detection at 260 nm.



12





Figure S9. HPLC trace of compound **13**. HPLC conditions: Phenomenex C₁₈, 10 micron, 3.9 x 300 mm column, 30 minute gradient of 10 → 70% MeCN/water (each with 0.05% TFA), 1 mL/minute, UV detection at 260 nm.



13




Figure S10. Chemiluminescence emission profiles of acridinium esters **9**, **13** and **14** in the absence of CTAC. Light emission was observed to be slow for all three acridinium esters in the absence of surfactant requiring more than 60 seconds for > 95% emission.




Figure S11. Apparent chemiluminescence stability of anti-HBsAg antibody conjugates of acridinium ester labels **9**, **13** and **14** at pH = 6.0 and 7.4 at 4°C. There was no discernible loss of chemiluminescence even after 30 days for all three labels.